Summit Therapeutics Inc.·4

Mar 8, 5:24 PM ET

Dhingra Ankur 4

4 · Summit Therapeutics Inc. · Filed Mar 8, 2023

Insider Transaction Report

Form 4
Period: 2023-03-07
Dhingra Ankur
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2023-03-07$1.05/sh+196,362$206,180234,558 total(indirect: By Trust)
Holdings
  • Common Stock

    39,527
Footnotes (2)
  • [F1]Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
  • [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Documents

1 file
  • 4
    wf-form4_167831424008442.xmlPrimary

    FORM 4